Blinklab Limited (AU:BB1) has released an update.
BlinkLab Limited has partnered with Columbia University to explore the impact of aerobic exercise on neuroplasticity in patients with Spinocerebellar Ataxias through an 18-month study. The study aims to establish BlinkLab’s eyeblink conditioning test as a biomarker for neuroplasticity, potentially advancing the global adoption of their AI-powered diagnostic platform for neurological disorders. This collaboration could lead to transformative insights in neuropsychiatric research, with the added benefit of potentially generating exclusive licensing opportunities for BlinkLab.
For further insights into AU:BB1 stock, check out TipRanks’ Stock Analysis page.
